Apollo Hospitals says it has collaborated with Precisio Biotix to bring “next-generation lysin” science to support India’s efforts against antimicrobial resistance (AMR). Both sources describe the initiative as part of Apollo’s broader work related to AMR, focusing on advanced approaches to fighting resistant infections. The reports frame the collaboration as a partnership intended to apply lysin science—an approach that uses engineered biological agents associated with targeting pathogens—to address challenges posed by AMR. The coverage does not provide detailed technical specifications, timelines, or trial outcomes in the information provided. However, it consistently identifies Apollo Hospitals as the healthcare organization initiating the partnership and Precisio Biotix as the technology and science collaborator. Overall, the articles present the move as a research and implementation collaboration aimed at strengthening strategies against AMR in India, without attributing specific claims beyond the stated focus on next-generation lysin science and the collaboration between the two organisations.